N-(1-adamantyl)-4-(1H-indol-3-yl)propanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-(1-adamantyl)-4-(1H-indol-3-yl)propanamide
• 英文别名: N-(1-adamantyl)-3-(1H-indol-3-yl)propanamide
• 化学式: C₂₁H₂₆N₂O
• 分子量: 322.45
• InChiKey: CIMWXWBFMPWXBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  44.9
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(1-adamantyl)-4-(1H-indol-3-yl)propanamide 在 三乙基硅烷 作用下， 以 三氟乙酸 为溶剂， 生成 N-Adamantan-1-yl-3-(2,3-dihydro-1H-indol-3-yl)-propionamide
  参考文献：
  名称：

  The Ideal Synthetic Method Aimed at the Leads for an a2-Blocker, an Inhibitor of Blood Platelet Aggregation, and an Anti-osteoporosis Agent

  摘要：

  According to the definition of the ideal synthetic method, an example aimed at the leads for an alpha(2)-blocker, an inhibitor of platelet aggregation, and an anti-osteoporosis agent is established starting from tryptamine. The originality rate, the intellectual property, and the application potential factors of the method are 71, 54, and 100, respectively. The method employs only conventional reagents and reaction conditions without using any protecting groups.

  DOI：

  10.3987/com-06-10771
• 作为产物：
  描述：

  3-吲哚丙酸 、 金刚烷胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.17h， 以88%的产率得到N-(1-adamantyl)-4-(1H-indol-3-yl)propanamide
  参考文献：
  名称：

  带有磺酰胺和三唑药效基团的新型吲哚酰胺衍生物的合成和抗血浆活性。

  摘要：

  由于最近有报道称寄生虫对青蒿素和其他抗疟药的耐药性不断增强，因此开发新的抗疟化学型已成为当务之急。在这里，我们报告了一系列采用磺胺和三唑药效基团的金刚烷基/环庚基吲哚酰胺衍生物，它们采用了不同的化学修饰，并评估了它们的体外抗血浆活性。在所有吲哚酰胺中，具有磺酰胺药效基团的化合物22、24、26和30对CQ敏感的Pf3D7菌株的IC50为1.87、1.93、2.00、2.17μM，对CQ耐药的PfK1菌株的IC50为1.69、2.12、1.60、2.19μM，分别。

  DOI：

  10.1016/j.ejmech.2017.03.010

文献信息

• Receptor Blocker and Vasodilator Comprising Indole Derivative as Active Ingredient
  申请人：Somei Masanori

  公开号：US20090005430A1

  公开（公告）日：2009-01-01

  It is intended to find a compound that is structurally simpler than yohimbine, a pentacyclic condensed heterocyclic compound, and has an effect similar to that of yohimbine. The present invention relates to a pharmaceutical or food composition for α 2 receptor blockage comprising a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: (wherein R 1 represents a hydrogen, alkyl group, alkenyl group, alkynyl group, aromatic group, aralkyl group, acyl group, arylsulfonyl group, alkylsulfonyl group, or hydroxyl group; R 2 represents a hydrocarbon group; R 3 , R 4 , R 5 , R 6 , and R 7 are the same or different and represent a hydrogen, halogen, alkyl group, or alkoxy group; R 8 represents a hydrogen or acyl group; n represents an integer of 1 to 6; and a and b are the same or different and represent 1 or 0).
• US7872040B2
  申请人：——

  公开号：US7872040B2

  公开（公告）日：2011-01-18
• The Ideal Synthetic Method Aimed at the Leads for an a2-Blocker, an Inhibitor of Blood Platelet Aggregation, and an Anti-osteoporosis Agent
  作者：Masanori Somei、Takako Iwaki、Fumio Yamada、Yoshio Tanaka、Koki Shigenobu、Katsuo Koike、Nobuo Suzuki、Atsuhiko Hattori

  DOI：10.3987/com-06-10771

  日期：——

  According to the definition of the ideal synthetic method, an example aimed at the leads for an alpha(2)-blocker, an inhibitor of platelet aggregation, and an anti-osteoporosis agent is established starting from tryptamine. The originality rate, the intellectual property, and the application potential factors of the method are 71, 54, and 100, respectively. The method employs only conventional reagents and reaction conditions without using any protecting groups.
• Synthesis and antiplasmodial activity of novel indoleamide derivatives bearing sulfonamide and triazole pharmacophores
  作者：N. Devender、Sarika Gunjan、Renu Tripathi、Rama Pati Tripathi

  DOI：10.1016/j.ejmech.2017.03.010

  日期：2017.5

  in, we report a novel series of adamantyl/cycloheptyl indoleamide derivatives bearing sulfonamide and triazole pharmacophores adopting different chemical modifications and evaluated them for antiplasmodial activity in vitro. Among all the indoleamides, compounds 22, 24, 26 and 30 with sulfonamide pharmacophore showed promising activity with IC50 of 1.87, 1.93, 2.00, 2.17 μM against CQ sensitive Pf3D7

  由于最近有报道称寄生虫对青蒿素和其他抗疟药的耐药性不断增强，因此开发新的抗疟化学型已成为当务之急。在这里，我们报告了一系列采用磺胺和三唑药效基团的金刚烷基/环庚基吲哚酰胺衍生物，它们采用了不同的化学修饰，并评估了它们的体外抗血浆活性。在所有吲哚酰胺中，具有磺酰胺药效基团的化合物22、24、26和30对CQ敏感的Pf3D7菌株的IC50为1.87、1.93、2.00、2.17μM，对CQ耐药的PfK1菌株的IC50为1.69、2.12、1.60、2.19μM，分别。